Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting – GlobeNewswire
stemadminIPS Stem CellsNo comments

Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event on Friday, December 4 SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that four oral and eight poster presentations for the Companys induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually from December 5-8, 2020.

Read more
Global Induced Pluripotent Market Business Share, Industry Size and Future Investment Opportunities by 2026||Bristol-Myers Squibb Company; CELGENE…
stemadminIPS Stem CellsNo comments

Induced pluripotent market is expected to rise to an estimated value of USD 2.33 billion by 2026, registering a substantial CAGR in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing prevalence of chronic diseases and ailments requiring the development of modern technologically advanced therapeutic options. Few of the major competitors currently working in the induced pluripotent market areBristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Read more
The Stem Cell-Derived Cells market to be in conjunction to growth from 2020 to 2030 – PRnews Leader
stemadminIPS Stem CellsNo comments

Stem cell-derived cells are ready-made human induced pluripotent stem cells (iPS) and iPS-derived cell lines that are extracted ethically and have been characterized as per highest industry standards. Stem cell-derived cells iPS cells are derived from the skin fibroblasts from variety of healthy human donors of varying age and gender. These stem cell-derived cells are then commercialized for use with the consent obtained from cell donors

Read more
Induced Pluripotent Stem Cells (iPSCs) Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By…
stemadminIPS Stem CellsNo comments

Induced Pluripotent Stem Cells (iPSCs) Market Forecast 2020-2026 The Global Induced Pluripotent Stem Cells (iPSCs) Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market.

Read more
The Induced Pluripotent Stem Cells Market To Witness A Major Breakthrough In The Form Of A Double-Digit CAGR Of 7% – KYT24
stemadminIPS Stem CellsNo comments

Market Report Summary For Full Information -> Click Here Read Full Press Release Below The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

Read more
QurAlis Announces Appointment of New Chief Medical Officer and Formation of Clinical Advisory Board – BioSpace
stemadminIPS Stem CellsNo comments

Oct. 29, 2020 12:00 UTC Rare disease and neurology expert Dr. Angela Genge to lead QurAlis clinical R&D for ALS and FTD CAMBRIDGE, Mass.--(BUSINESS WIRE)-- QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the appointment of Angela Genge, MD, FRCP(C), eMBA to the position of Chief Medical Officer (CMO)

Read more
SFARI | New collaboration between SFARI and Nancy Lurie Marks Family Foundation will generate hundreds of iPSC lines for autism research – SFARI News
stemadminIPS Stem CellsNo comments

The Simons Foundation Autism Research Initiative (SFARI) and the Nancy Lurie Marks Family Foundation (NLMFF) are pleased to announce that they joined efforts to generate induced pluripotent stem cells (iPSCs) from blood samples of participants in Simons Searchlight. With an investment of $450,000 from each organization, SFARI and NLMFF intend to generate iPSCs from 100 individuals over the next year. They plan to possibly generate another 100 iPSCs during a second year of the collaboration

Read more
Kobe Hospital Trials Transplant to Reverse Blindness A First in the World – JAPAN Forward
stemadminIPS Stem CellsNo comments

Kobe City Eye Hospital in Hyogo Prefecture announced on October 16 that it had performed the worlds first clinical trial transplant to reverse blindness. The transplant was performed in early October on a woman in her 60s from the Kansai region who had lost most of her eyesight. The roughly two-hour surgery wrapped up as scheduled without the patient experiencing complications

Read more

Theme: Illdy.